Highlights

  • FY26 revenue reached $10.8 billion, an increase of 15.5% on the normalised pro-forma comparison.
  • Normalised EBIT rose 20.6% to $1,090.0 million as the combined business completed its first full financial year.
  • Integration synergies reached $32.6 million during FY26.
  • The Australian segment reported 14.9% revenue growth while international segment EBIT rose 91.3%.
  • Net debt reduced to $663 million at 30 June 2026.

Sigma Healthcare Limited (ASX:SIG) operates a retail pharmacy franchise network and a full-line pharmaceutical wholesale business supplying community pharmacies. Its Australian retail brands include Chemist Warehouse, Amcal and Discount Drug Stores, alongside international pharmacy operations. During FY26, the group reported its first full-year results following the Chemist Warehouse merger, with distribution operations, franchise expansion and integration expenditure shaping its financial performance.

FY26 Revenue and Earnings

For the year ended 30 June 2026, Sigma Healthcare Limited (ASX:SIG) reported revenue of $10.8 billion, up 15.5% compared with normalised pro-forma FY25 figures. Normalised earnings before interest and tax (EBIT) increased 20.6% to $1,090.0 million, taking the normalised EBIT margin to 10.1%. These comparisons use the company’s normalised pro-forma basis rather than an unadjusted statutory comparison.

Normalised net profit after tax was $732.3 million, representing a 22.3% increase on the same comparison basis. Normalised results are management-defined measures and should be distinguished from statutory earnings. Sigma Healthcare Limited (ASX:SIG) reported these figures in its August 2026 full-year results release, alongside segment performance and the progress of integration initiatives.

Australian Pharmacy Network and Distribution

The Australian business combines franchise support, community pharmacy retailing and pharmaceutical wholesaling. Sigma Healthcare Limited (ASX:SIG) reported 14.9% revenue growth in its Australian segment during FY26, with segment normalised EBIT increasing 18.3%. The company’s network encompasses branded pharmacies with different retail propositions, while its distribution infrastructure supports the supply of prescription medicines and other healthcare products.

Warehouse operations are relevant because pharmaceutical wholesale distribution depends on inventory availability, order accuracy, transport coordination and reliable servicing of pharmacy customers. Automation and distribution efficiency are operational considerations, but the FY26 company release does not quantify a standalone earnings contribution from automated picking equipment. Such a contribution has therefore not been assumed.

Integration Programme and International Operations

Sigma Healthcare Limited (ASX:SIG) recorded $32.6 million in integration synergies during FY26. The group stated that its integration programme was progressing towards a company objective of $100 million in annual synergies by FY29. That amount is a management target rather than a realised result, and delivery depends on subsequent integration work and operating execution.

International operations also contributed to the annual outcome. The company reported international segment EBIT of $55.8 million, an increase of 91.3%, and indicated that Ireland became profitable for the first time. Its international pharmacy activities extend to New Zealand, Ireland, Dubai and China. Geographic expansion creates additional operational complexity, including different regulatory, logistics and customer requirements.

Balance Sheet and Operating Considerations

At 30 June 2026, Sigma Healthcare Limited (ASX:SIG) reported net debt of $663 million and a net debt-to-normalised EBITDA ratio of 0.57 times. These measures help explain the group’s disclosed funding position following integration activity. They do not, by themselves, establish the cost or expected return of planned distribution investment.

Key operational considerations include working capital tied to pharmaceutical inventory, supplier relationships, franchise service standards and the cost of running distribution facilities. The company’s mix of wholesale and pharmacy franchise activities also requires coordination between retail network planning and product availability. Changes in operating costs, regulatory requirements and integration timing can influence reported margins.

Key Insights

Sigma Healthcare Limited (ASX:SIG) reported higher FY26 revenue and normalised earnings across its combined pharmacy business, together with measurable merger integration synergies. Australian wholesale and franchise operations remained central to group activity, while international operations contributed to EBIT growth. The distinction between completed FY26 results and the FY29 synergy target is important when interpreting the company’s disclosures.